Abbvie inc ABBV.US Overview Analysis
ABBV AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has achieved the highest rating for both its value and dividend scores. It's a prime choice for long-term accumulation. For optimal entry, check our trend or swing trading rating.
ABBV Current Performance
-1.33%
Abbvie inc
1.31%
Avg of Sector
0.58%
S&P500
Top 10 High Relevance to ABBV
- AMGN Amgen incValue 4Trend 2Swing Trading 4Whale Interest 4Dividend 5See more
ABBV Profile
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Its Immunology products include rheumatology, dermatology and gastroenterology. Its Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere, and Epkinly. The Company's Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Its Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and Other eye care. Its Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its Venclexta is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers.